What it's for (Indications)
- Rho(D) Immune Globulin (Human) is indicated for the prevention of Rh alloimmunization in Rh-negative individuals, particularly in obstetric settings.
- This includes antenatal prophylaxis during the third trimester (typically around 28-30 weeks of gestation) and postpartum administration following the delivery of an Rh-positive infant.
- It is also crucial for Rh-negative women who experience obstetric complications or procedures that may lead to fetomaternal hemorrhage, such as miscarriage, abortion (spontaneous or induced), ectopic pregnancy, threatened abortion, antepartum hemorrhage (e.
- g.
- , placenta previa, abruptio placentae), amniocentesis, chorionic villus sampling (CVS), percutaneous umbilical blood sampling (PUBS), external cephalic version, or significant abdominal trauma during pregnancy.
- Furthermore, it is indicated for Rh-negative individuals who have received transfusions of Rh-positive blood or blood components.
- A distinct indication for certain preparations, including Rhophylac, is the treatment of immune thrombocytopenic purpura (ITP) in Rh-positive, non-splenectomized children and adults to temporarily raise platelet counts and reduce the risk of bleeding.
- This broad utility underscores its critical role in preventing hemolytic disease of the fetus and newborn (HDFN) and managing specific hematological disorders.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of Rho(D) Immune Globulin (Human) varies significantly based on the indication, product concentration, and route of administration (intramuscular [IM] or intravenous [IV]). For antenatal prophylaxis in Rh-negative pregnant women, a common regimen involves administering a single dose (e.g., 300 mcg or 1500 IU) typically between 28 and 30 weeks of gestation. A subsequent dose (e.g., 300 mcg) is usually administered within 72 hours of delivering an Rh-positive infant. Following obstetric complications or procedures potentially causing fetomaternal hemorrhage, an appropriate dose (e.g., 300 mcg for events before 12 weeks, and often a larger dose for later events or significant bleeds based on estimated fetomaternal bleed volume) should be given as soon as possible, ideally within 72 hours. For incompatible Rh-positive blood transfusions, the dose is calculated based on the estimated volume of transfused Rh-positive red blood cells, requiring a higher and potentially repeated administration. For the treatment of Immune Thrombocytopenic Purpura (ITP), the dosage is substantially different, typically administered intravenously at higher doses (e.g., 50 mcg/kg or 250 IU/kg initially) with subsequent monitoring and potential retreatment based on platelet response and clinical status. Precise dosing information, including IM/IV administration guidelines, must always be referenced from the specific product's prescribing information. |
Safety & Warnings
Common Side Effects
- As with any biologic product, administration of Rho(D) Immune Globulin (Human) can be associated with a range of side effects, though most are mild and transient.
- Common reactions at the injection site for intramuscular administration include pain, tenderness, swelling, redness, and induration.
- Systemic reactions may include headache, dizziness, mild fever, chills, malaise, and asthenia.
- Nausea and vomiting have also been reported.
- Less common but more significant reactions involve hypersensitivity phenomena, manifesting as skin rash, pruritus, or urticaria; severe allergic reactions, including anaphylaxis, are rare but possible and require immediate medical intervention.
- When administered intravenously, especially for the treatment of Immune Thrombocytopenic Purpura (ITP), there is a risk of more serious adverse events such as intravascular hemolysis, acute renal failure, and, rarely, disseminated intravascular coagulation (DIC).
- Other rare but serious adverse events include thromboembolic events (e.
- g.
- , deep vein thrombosis, pulmonary embolism), and transfusion-related acute lung injury (TRALI).
- Patients should be carefully monitored for signs of these severe reactions following administration.
Serious Warnings
- Black Box Warning: WARNING: INTRAVASCULAR HEMOLYSIS (IVH) IN ITP PATIENTS Serious and fatal intravascular hemolysis (IVH) has been reported in patients treated with Rho(D) Immune Globulin (Human) for Immune Thrombocytopenic Purpura (ITP). IVH can lead to acute renal failure, disseminated intravascular coagulation (DIC), and death. Patients with pre-existing renal impairment, diabetes mellitus, or those at increased risk of thrombosis may be particularly susceptible due to compromised physiological reserves or increased fragility of red blood cells. The risk appears to be dose-dependent and is higher with intravenous administration. Close monitoring for signs and symptoms of IVH is crucial for at least 8 hours after administration, and for patients receiving the product for ITP, post-infusion monitoring of renal function and urine color should continue for 24 hours or longer, as clinically indicated. If signs or symptoms of IVH occur, including but not limited to back pain, shaking chills, fever, dark urine, or a sudden decrease in hemoglobin, promptly measure plasma-free hemoglobin and urine haptoglobin. Treatment should be discontinued immediately if IVH is suspected. Renal function should be closely monitored, and appropriate medical management, including hydration, diuretics, and aggressive supportive care, should be initiated. The risk of IVH is significantly lower when Rho(D) Immune Globulin (Human) is used for its primary indication of Rh prophylaxis in Rh-negative patients. However, vigilance for any adverse reactions, including allergic responses, remains important across all indications.
- Several critical warnings are associated with the use of Rho(D) Immune Globulin (Human) to ensure patient safety.
- Hypersensitivity reactions, including severe anaphylactic reactions, are possible, even in individuals who have previously tolerated the product.
- Patients should be observed for an appropriate period following administration.
- The product contains a small amount of IgA, and individuals with selective IgA deficiency who have known antibodies to IgA are at an increased risk of developing severe hypersensitivity or anaphylactic reactions.
- This product should not be administered to Rh-positive individuals except in the specific context of Immune Thrombocytopenic Purpura (ITP) therapy.
- For ITP patients, particularly those with pre-existing conditions like renal impairment, diabetes, or dehydration, or those receiving high IV doses, there is a heightened risk of acute renal failure and intravascular hemolysis.
- Thromboembolic events have been reported with immunoglobulin products; caution is advised in patients with pre-existing risk factors.
- Administration of Rho(D) Immune Globulin may interfere with the immune response to live attenuated virus vaccines (e.
- g.
- , measles, mumps, rubella, varicella), requiring a delay in vaccination or repetition of vaccination.
- Furthermore, administration to the mother may result in a positive direct Coombs test in the infant, complicating neonatal assessment for hemolytic disease.
How it Works (Mechanism of Action)
Rho(D) Immune Globulin (Human) exerts its therapeutic effects through distinct mechanisms depending on the indication. For the prevention of Rh alloimmunization, the primary mechanism involves passive immunization. When an Rh-negative individual is exposed to Rh-positive red blood cells (e.g., during pregnancy with an Rh-positive fetus or incompatible transfusion), the administered anti-D immunoglobulin (IgG antibodies specifically directed against the Rho(D) antigen) binds to these foreign Rh-positive red blood cells. This coating of Rh-positive red blood cells by anti-D antibodies effectively 'masks' them, preventing their recognition by the Rh-negative individual's own immune system. The antibody-coated red blood cells are then rapidly cleared from circulation and destroyed by the reticuloendothelial system, primarily the spleen, before the recipient's B cells can be activated to produce an endogenous, long-lasting anti-D antibody response. This process, known as immune suppression or antigen deviation, prevents active Rh sensitization and the subsequent development of hemolytic disease of the fetus and newborn (HDFN) in future Rh-positive pregnancies. In the context of Immune Thrombocytopenic Purpura (ITP) in Rh-positive individuals, the mechanism is not fully elucidated but is thought to involve Fc receptor blockade. The anti-D antibodies bind to the patient's own Rh-positive red blood cells, forming antibody-coated red blood cell complexes. These complexes then preferentially bind to Fc receptors on macrophages within the reticuloendothelial system (e.g., spleen), effectively saturating these receptors. This saturation diverts the macrophages from destroying antibody-coated platelets, which are typically targeted in ITP, thereby preserving platelet counts. Additionally, other immune modulatory effects, such as a decrease in autoantibody production and alteration of T-cell function, may contribute to the therapeutic effect in ITP.